Medicare Enrolled
Dr. Jeffrey Bubis, DO
Medical Oncology · Fleming Island, FL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Bubis from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Bubis?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Bubis
Dr. Jeffrey Bubis is a medical oncology specialist in Fleming Island, FL, with 20 years of NPI registration. Based on federal Medicare data, Dr. Bubis performed 29,629 Medicare services across 1,807 unique beneficiaries.
Between the years covered by Open Payments, Dr. Bubis received a total of $73,594 from 81 pharmaceutical and/or device companies across 537 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Bubis is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 40% volume in FL
$73,594 industry payments
Florida License Status
FL DOH · MQA1
Active license
None
Board action on record
0
Recent admin complaints
| Profession | License # | Status | Expires | Board Action |
|---|---|---|---|---|
| Osteopathic Physician | 9446 | Clear | March 31, 2028 | — |
Data from Florida Department of Health Medical Quality Assurance.
License records are public under Chapter 119, Florida Statutes.
Verify directly on FL DOH →
Medicare Practice Summary
Medicare Utilization ↗29,629
Medicare services
Top 40% in FL for medical oncology
1,807
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,481 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (aprepitant) | 7,670 | $1 | $5 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
6,380 | $6 | $23 |
| Iron infusion (Monoferric) | 4,800 | $16 | $57 |
| Denosumab injection (Prolia/Xgeva) | 2,700 | $18 | $51 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,910 | $0 | $3 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,221 | $8 | $9 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,105 | $8 | $29 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
635 | $64 | $239 |
| Anti-nausea injection (Aloxi/palonosetron) | 570 | $1 | $28 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
504 | $97 | $339 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
397 | $10 | $69 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
353 | $22 | $84 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
261 | $97 | $378 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
204 | $46 | $189 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
155 | $6 | $69 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
113 | $1 | $3 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
97 | $1 | $6 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
85 | $21 | $79 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
73 | $125 | $453 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
67 | $11 | $61 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
62 | $2 | $7 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
58 | $49 | $178 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
47 | $25 | $156 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
44 | $10 | $42 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
41 | $18 | $59 |
| Automated urinalysis An automated laboratory test performed on a urine sample to analyze its chemical and physical properties. The procedure uses machinery to detect various substances and cells within the urine. |
32 | $2 | $8 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
29 | $28 | $156 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
16 | $137 | $556 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
19.5% high complexity
68.1% medium
12.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$73,594
Total received (2018-2024)
Avg $10,513/year across 7 years
Top 11% in FL for medical oncology
81
Companies
537
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$41,217 (56.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$25,124 (34.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,253 (9.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$11,298
2023
$19,784
2022
$6,828
2021
$8,194
2020
$11,298
2019
$6,273
2018
$9,919
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$11,929
AstraZeneca Pharmaceuticals LP
$9,722
Blueprint Medicines Corporation
$7,456
NOVARTIS PHARMACEUTICALS CORPORATION
$5,306
JAZZ PHARMACEUTICALS INC.
$4,305
Seagen Inc.
$3,604
Exelixis Inc.
$3,292
Novartis Pharmaceuticals Corporation
$3,017
Novocure Inc.
$2,996
GENZYME CORPORATION
$2,716
Pharmacosmos Therapeutics Inc.
$2,453
Astellas Pharma US Inc
$2,412
E.R. Squibb & Sons, L.L.C.
$2,327
Genentech USA, Inc.
$1,734
Coherus Biosciences Inc.
$1,088
Stemline Therapeutics Inc.
$1,080
AVEO Pharmaceuticals, Inc.
$916
Alexion Pharmaceuticals, Inc.
$852
TerSera Therapeutics LLC
$827
BeiGene, Ltd.
$500
Merck Sharp & Dohme Corporation
$495
BeiGene USA, Inc.
$431
Janssen Biotech, Inc.
$360
Amgen Inc.
$340
Takeda Pharmaceuticals U.S.A., Inc.
$295
Merck Sharp & Dohme LLC
$234
Gilead Sciences, Inc.
$231
Lilly USA, LLC
$231
GlaxoSmithKline, LLC.
$149
Daiichi Sankyo Inc.
$146
Celgene Corporation
$140
Kite Pharma, Inc.
$118
EMD Serono, Inc.
$115
Foundation Medicine, Inc.
$105
Seattle Genetics, Inc.
$96
Eisai Inc.
$96
Ipsen Biopharmaceuticals, Inc
$90
Mirati Therapeutics, Inc.
$86
Rigel Pharmaceuticals, Inc.
$72
Incyte Corporation
$69
Global Blood Therapeutics, Inc.
$67
Bayer HealthCare Pharmaceuticals Inc.
$66
Taiho Oncology, Inc.
$63
EISAI INC.
$63
TESARO, Inc.
$53
AbbVie Inc.
$52
CSL Behring
$49
MorphoSys, US Inc.
$39
G1 Therapeutics, Inc.
$39
TAIHO ONCOLOGY, INC.
$37
ABBVIE INC.
$37
Epizyme, Inc.,
$36
ARRAY BIOPHARMA INC
$35
Lexicon Pharmaceuticals, Inc.
$32
Regeneron Healthcare Solutions, Inc.
$32
MEDIVATION FIELD SOLUTIONS LLC
$31
Bayer Healthcare Pharmaceuticals Inc.
$28
Alnylam Pharmaceuticals Inc.
$28
Aurobindo Pharma USA, Inc.
$26
SANOFI-AVENTIS U.S. LLC
$24
Fennec Pharmaceuticals, Inc.
$24
Lundbeck LLC
$23
Agios Pharmaceuticals, Inc.
$22
Apellis Pharmaceuticals, Inc.
$21
Aveo Pharmaceuticals, Inc.
$19
Dova Pharmaceuticals
$19
Array BioPharma Inc.
$18
Emmaus Medical, Inc.
$18
TG Therapeutics, Inc.
$17
ADC Therapeutics America, Inc.
$17
Immunocore Limited
$14
Puma Biotechnology, Inc.
$13
Karyopharm Therapeutics Inc.
$13
INSYS Therapeutics Inc
$13
Adaptive Biotechnologies Corporation
$13
Deciphera Pharmaceuticals Inc.
$13
AbbVie, Inc.
$12
Pharmacyclics LLC, An AbbVie Company
$12
Helsinn Therapeutics (U.S.), Inc.
$11
Sirtex Medical Inc
$10
Veracyte, Inc.
$2
Top 3 companies account for 39.6% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · ALUNBRIG · AYVAKIT · Alecensa · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · Braftovi · CABOMETYX · CALQUENCE · COSELA · CYRAMZA · Cabometyx · DARZALEX · Doptelet · ELAHERE · ELREXFIO · EMPLICITI · ENHERTU · ERLEADA · Empaveli · Endari · Enhertu · Erivedge · Erleada · FEMARA · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · GAVRETO · GAZYVA · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · Idelvion · Imbruvica · JADENU · JAKAFI · JEVTANA · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · Monoferric · NERLYNX · NINLARO · Neulasta · Nexavar · Nplate · Nubeqa · OCREVUS · OJJAARA · ONPATTRO · OPDIVO · OPDUALAG · OXBRYTA · Oncology · Onivyde · Orserdu · PADCEV · PIQRAY · PLUVICTO · POLIVY · PROMACTA · Padcev · Pedmark · Perjeta · QINLOCK · REBLOZYL · RYBREVANT · RYDAPT · SANDOSTATIN · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SUTENT · SYNDROS · Soliris · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Trodelvy · UKONIQ · ULTOMIRIS · VENCLEXTA · VERZENIO · VIJOICE · VOTRIENT · VYEPTI · VYXEOS · Venclexta · Vyloy · XALKORI · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · Xtandi · Yescarta · ZEJULA · Zevalin · Zoladex · Zydelig · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (56%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $248 per 100 Medicare services performed
Geographic Context
Medical oncologists within 10 mi
13
Per 100K population
5.8
County median income
$86,094
Nearest hospital
HCA FLORIDA ORANGE PARK HOSPITAL
5.3 mi
5.3 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Bubis is a mixed practice specialist, with moderate Medicare volume, with consulting-driven industry engagement in the top 11% of FL peers, with 20 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Bubis experienced with anti-nausea injection (aprepitant)?
Based on Medicare claims data, Dr. Bubis performed 7,670 anti-nausea injection (aprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Bubis receive payments from pharmaceutical companies?
Yes. Dr. Bubis received a total of $73,594 from 81 companies across 537 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Bubis's costs compare to other medical oncologists in Fleming Island?
Dr. Bubis's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Bubis) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Fleming Island
Browse medical oncologists in Fleming Island ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in FL
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in FL
Which FL medical oncologists receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Blueprint Medicines Corporation Payments to Doctors
See all physicians who received payments from Blueprint Medicines Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology